Evidence map›Paper›PMID 38424059›Full record

ArticleNPJ Parkinson's disease2024

Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson's disease phenotypes.

Silke Nuber, Xiaoqun Zhang, Thomas D McCaffery, Tim E Moors, Marie-Alexandre Adom, Wolf N Hahn, Dylan Martin, Maria Ericsson, Arati Tripathi, Ulf Dettmer and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Olfactory deficit and gastrointestinal dysfunction precede motor abnormalities in alpha-Synuclein G51D knock-in mice.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Review
  9. Frontiers in molecular neuroscience · 2024
    Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Silke NuberAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. snuber@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-2124-6865
Xiaoqun ZhangNeuro Svenningsson, Department of Clinical Neuroscience, Karolinska Institutet, 17176, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-9461-8682
Thomas D McCafferyAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Tim E MoorsAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0003-2223-9947
Marie-Alexandre AdomAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Wolf N HahnAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0009-0008-1154-9281
Dylan MartinAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0009-0000-9205-6930
Maria EricssonElectron Microscopy Laboratory, Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-4563-3683
Arati TripathiAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Ulf DettmerAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0001-6676-0107
Per SvenningssonNeuro Svenningsson, Department of Clinical Neuroscience, Karolinska Institutet, 17176, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-6727-3802
Dennis J SelkoeAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0001-8846-9767
Brigham and Women's Hospital · USKarolinska Institutet · SEHarvard University · US

Funding

Elucidating the Biological Differences Between Distinct Fibrillar and Non-Fibrillar Alpha-Synuclein Inclusions in Human Stem-Cell ModelsR01NS109209 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI KHURANA, VIKRAM · 2020 to 2024
$4.5M
Biology of Native Alpha-Synuclein Tetramers in Parkinson's DiseaseRF1NS083845 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SELKOE, DENNIS J · 2020 to 2020
$2.9M
Polo-like-kinase-2-dependent α-Synuclein Serine-129 Phosphorylation: a Physiological RoleDuring Synaptic ActivityRF1NS122880 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF, RAMALINGAM, NAGENDRAN · 2022 to 2022
$2.1M
Stabilizing native α-synuclein homeostasis to prevent insoluble α-synuclein aggregatesR01NS099328 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF · 2017 to 2021
$1.9M
Biologically novel mouse models of PD with progressive synucleinopathy and early-onset tremor and motor deficits responsive to L-DOPAR01NS109510 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI NUBER, SILKE · 2019 to 2023
$1.9M
Biology of Native Alpha-Synuclein Tetramers in Parkinson's DiseaseR01NS083845 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SELKOE, DENNIS J · 2014 to 2018
$1.8M
Biologically Novel Mouse Models of PD with Progressive Synucleinopathy and Early-Onset Tremor and Motor Deficits Responsive to L-DOPARF1NS109510 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI NUBER, SILKE · 2024 to 2024
$1.3M
Contrasting pathomechanisms of membrane versus cytosol alpha-synuclein excessR21NS121826 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF · 2021 to 2021
$505k
NINDS NIH HHS R01 NS083845NINDS NIH HHS R01 NS099328NINDS NIH HHS R01 NS109209NINDS NIH HHS R01 NS109510NINDS NIH HHS R21 NS121826NINDS NIH HHS RF1 NS083845NINDS NIH HHS RF1 NS109510NINDS NIH HHS RF1 NS122880
6 · The paper itself

Abstract

Mutations in the α-Synuclein (αS) gene promote αS monomer aggregation that causes neurodegeneration in familial Parkinson's disease (fPD). However, most mouse models expressing single-mutant αS transgenes develop neuronal aggregates very slowly, and few have dopaminergic cell loss, both key characteristics of PD. To accelerate neurotoxic aggregation, we previously generated fPD αS E46K mutant mice with rationally designed triple mutations based on the α-helical repeat motif structure of αS (fPD E46K→3 K). The 3 K variant increased αS membrane association and decreased the physiological tetramer:monomer ratio, causing lipid- and vesicle-rich inclusions and robust tremor-predominant, L-DOPA responsive PD-like phenotypes. Here, we applied an analogous approach to the G51D fPD mutation and its rational amplification (G51D → 3D) to generate mutant mice. In contrast to 3 K mice, G51D and 3D mice accumulate monomers almost exclusively in the cytosol while also showing decreased αS tetramer:monomer ratios. Both 1D and 3D mutant mice gradually accumulate insoluble, higher-molecular weight αS oligomers. Round αS neuronal deposits at 12 mos immunolabel for ubiquitin and pSer129 αS, with limited proteinase K resistance. Both 1D and 3D mice undergo loss of striatal TH+ fibers and midbrain dopaminergic neurons by 12 mos and a bradykinesia responsive to L-DOPA. The 3D αS mice have decreased tetramer:monomer equilibria and recapitulate major features of PD. These fPD G51D and 3D mutant mice should be useful models to study neuronal αS-toxicity associated with bradykinetic motor phenotypes.

Identifiers

PMID38424059
PMCPMC10904737
OpenAlexW4392283054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.